Century Therapeutics, Inc. Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount
Century Therapeutics, Inc. (IPSC) reported Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationTaxCreditsResearch · last filed 2026-08-12
- Century Therapeutics, Inc. effective income tax rate reconciliation, tax credit, research, amount for the quarter ending 2026-06-30 was $0.00.
- Century Therapeutics, Inc. effective income tax rate reconciliation, tax credit, research, amount for the quarter ending 2026-03-31 was $0.00.
- Century Therapeutics, Inc. effective income tax rate reconciliation, tax credit, research, amount for the quarter ending 2025-12-31 was $4.59M, a 26.38% increase year-over-year.
- Century Therapeutics, Inc. effective income tax rate reconciliation, tax credit, research, amount for the quarter ending 2025-09-30 was $0.00.
- Century Therapeutics, Inc. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2025 was $4.59M, a 26.38% increase from fiscal 2024.
- Century Therapeutics, Inc. effective income tax rate reconciliation, tax credit, research, amount for fiscal 2024 was $3.63M.
| Period end | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 3 month | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 6 month | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 9 month | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $0.00 10-Q · filed 2026-08-12 | $4.59M derived: sum of 3 quarters · filed 2026-08-12 | $4.59M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-13 | $4.59M derived: sum of 2 quarters · filed 2026-05-13 | $4.59M derived: sum of 3 quarters · filed 2026-05-13 | $4.59M derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-12-31 | $4.59M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $4.59M derived: sum of 2 quarters · filed 2026-03-12 | $4.59M derived: sum of 3 quarters · filed 2026-03-12 | $4.59M 10-K · filed 2026-03-12 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $0.00 10-Q · filed 2025-11-13 | $3.63M derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-06-30 | $0.00 10-Q · filed 2025-08-14 | $0.00 10-Q · filed 2026-08-12 | $3.63M derived: sum of 3 quarters · filed 2026-05-13 | $3.63M derived: sum of 4 quarters · filed 2026-05-13 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-13 | $3.63M derived: sum of 2 quarters · filed 2026-05-13 | $3.63M derived: sum of 3 quarters · filed 2026-05-13 | $3.63M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $3.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $3.63M derived: sum of 2 quarters · filed 2026-03-12 | $3.63M derived: sum of 3 quarters · filed 2026-03-12 | $3.63M 10-K · filed 2026-03-12 |
| 2024-09-30 | $0.00 10-Q · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $0.00 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-08-14 | $0.00 10-Q · filed 2025-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |